FIELD: medicine.
SUBSTANCE: invention relates to the use of leucine, acetyl-leucine or their pharmaceutically acceptable salts for the treatment of a restless leg syndrome.
EFFECT: obtaining therapeutic agents for the treatment of neurodegenerative diseases.
11 cl, 14 dwg, 35 tbl, 22 ex
Authors
Dates
2021-12-29—Published
2018-02-15—Filed